Poly Medicure is moving key manufacturing lines to India following its acquisition of European firms Citieffe and PendraCare. The company plans to launch up to 30 new medical products annually by 2030 to substitute expensive imports. Investors should watch how the company balances its global export revenue with rising shipping and material costs.
Poly Medicure Ltd is reorienting its manufacturing strategy to focus more heavily on India. This follows the company’s recent acquisitions of Italy-based Citieffe Group and the Netherlands-based PendraCare Group. By integrating these international businesses into its Indian production chain, the company intends to lower manufacturing costs and build a more resilient local supply network.
To support this expansion, the company is preparing to open new production facilities in Haryana and at a medical park in Uttar Pradesh. The move is central to the company’s goal of replacing expensive imported medical devices with locally made alternatives. With a portfolio of over 390 patents, the company plans to launch 25 to 30 new products annually until 2030, specifically targeting high-demand medical segments like cardiac care, orthopaedics, nephrology, and oncology.
Financial and Operational Context
The company is targeting a revenue of approximately ₹2,300 crore for the current financial year, up from its existing revenue base of around ₹1,875 crore. Currently, about 70 percent of its revenue comes from exports, making it the second-largest player in India's medical devices sector. However, this export-heavy model faces several external pressures.
Risks and Market Headwinds
While the company is scaling its domestic capacity, it must navigate significant sector pressures. Global shipping disruptions, specifically in the Red Sea and Hormuz routes, have increased freight costs and created supply chain uncertainty. Additionally, rising plastic costs—a key raw material for medical devices—and shifting US tariff policies could pressure profit margins in the near term. These factors are critical for investors to track, as they can affect the speed at which the company achieves its growth targets.
What Investors Should Track Next
The success of this strategy will depend on how efficiently Poly Medicure can transfer its European research and development expertise to its Indian factories. The key monitorable for shareholders will be the commissioning timeline of the new facilities in Haryana and Uttar Pradesh. Investors may also watch whether the company can protect its profit margins while absorbing higher raw material and shipping costs, as these will directly influence its ability to reach the ₹2,300 crore revenue target.